Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

By C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, R. Hoover. Journal of the American Medical Association (JAMA), 2000

1,097 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/92d02f346e480866d56fb240d9cfdb51e9a2ab2a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. F. Bray
2. Rudolf Kaaks

In Oncology

1. F. Bray
2. D. Parkin
3. Rudolf Kaaks
4. J. Ferlay
5. A. Jemal

Citations in the corpus

• The pros and cons of phytoestrogens (2010, neutral): “Although pharmaceutical hormone replacement therapy is effective in most cases, this option has fallen out of favor because of fears that its use increases the risk of developing breast cancer risk [238,27].”
• Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. (2003, background): “... age, history of benign breast disease (atypia status unknown in WHI), age atmenarche,ageatfirstlivebirth,race/ ethnicity,andnumbersofmothersand sisters with breast cancer; (2) duration and recency of menopausal hormone therapy and oral contraceptive use;(3)bodymassindex(calculatedas weight in ki”
• Cancer burden in the year 2000. The global picture. (2001, background): “5to 2-fold) in long-term users [67], while a combined regimen of oestrogen and progestin has been shown to be associated with greater increases in risk than oestrogen alone [68].”
• Energy balance and cancer: the role of insulin and insulin-like growth factor-I (2001, background): “The oestrogen-plus-progestogen hypothesis may explain why post-menopausal hormone-replacement therapy with oestrogens plus progestogens appears to increase breast cancer risk more than the use of exogenous oestrogens alone (Ross et al. 2000; Schairer et al. 2000).”
• Menopausal hormone replacement therapy and risk of ovarian cancer. (2002, background): “women diagnosed as having breast cancer during the BCDDP; (2) all 25114 women who underwent breast surgery during the BCDDP, but had no evidence of malignant disease; (3) all 9628 women who were recommended by the BCDDP for surgical consultation, but for whom neither biopsy nor aspiration was perfor”